Form 4: MANGOCEUTICALS CFO Sells 5,000 Shares Under 10b5-1 Plan

MANGOCEUTICALS, INC. CFO Eugene M. Johnston sold 5,000 shares of common stock for $1.195 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Eugene M. Johnston, CFO of MANGOCEUTICALS, INC. (MGRX), sold 5,000 shares of common stock.
• The transaction occurred on December 9, 2025, at a weighted average price of $1.195 per share.
• The sale was executed under a Rule 10b5-1(c) trading plan.
• Following this transaction, Mr. Johnston directly beneficially owns 123,333 shares of MANGOCEUTICALS, INC. common stock.
• The shares were sold in multiple trades at prices ranging from $1.19 to $1.21.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale by a key executive. While the 10b5-1 plan provides some mitigation by indicating a pre-planned transaction, the reduction in direct ownership can still be interpreted as a lack of strong conviction or a move to diversify.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, indicating a pre-arranged and transparent transaction not based on immediate insider information.
• The CFO retains a significant direct beneficial ownership of 123,333 shares after the sale.

Negatives

• An insider sale by a key executive (CFO) can be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.

Risks

• Investor sentiment may be negatively impacted by the CFO's sale of shares, potentially leading to downward pressure on the stock price.

Industry Context

This filing is specific to MANGOCEUTICALS, INC. and its CFO's personal stock transactions, and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the CFO's sale of shares as a negative signal regarding the company's future prospects or current valuation.

Key Dates

Recommendation

The sale of shares by a CFO, even under a pre-arranged 10b5-1 plan, can be interpreted as a neutral to slightly negative signal. While the 10b5-1 plan suggests the sale is not based on immediate adverse news, it still represents a reduction in insider ownership. Without additional financial or operational context, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader company performance rather than making a strong buy or sell decision based solely on this insider transaction.

Keywords

MANGOCEUTICALS, MGRX, Eugene M Johnston, CFO, Insider Sale, Form 4, 10b5-1 plan, Stock Transaction, Beneficial Ownership